Pharmagreen Biotech Inc Financials
This page shows Pharmagreen Biotech Inc (PHBI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Pharmagreen Biotech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Pharmagreen Biotech Inc's current ratio of 0.11 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Pharmagreen Biotech Inc passes 1 of 9 financial strength tests. 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Pharmagreen Biotech Inc generates $0.49 in operating cash flow (-$427K OCF vs -$876K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Pharmagreen Biotech Inc reported -$876K in net income in fiscal year 2022.
Cash & Balance Sheet
Pharmagreen Biotech Inc held $8K in cash against $0 in long-term debt as of fiscal year 2022.
Pharmagreen Biotech Inc had 424M shares outstanding in fiscal year 2022. This represents an increase of 11.3% from the prior year.
Margins & Returns
Capital Allocation
PHBI Income Statement
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $597-38.0% | $963 | N/A | N/A | $0 | $0 | N/A | N/A |
| Cost of Revenue | $389-60.5% | $985 | N/A | N/A | $0 | $0 | N/A | N/A |
| Gross Profit | $208+1045.5% | -$22 | N/A | N/A | $0 | $0 | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | -$3K-122.6% | $14K-18.8% | $18K | N/A | $16K-21.8% | $21K-23.2% | $27K | N/A |
| Operating Income | N/A | -$188K-3.8% | -$181K | N/A | -$241K | N/A | -$204K | N/A |
| Interest Expense | $8K+1.1% | $8K-2.2% | $8K | N/A | $11K+6.8% | $10K-0.2% | $10K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$163K | N/A | -$39K | N/A | $252K | N/A | $19K | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | $0.00 | N/A | N/A | N/A |
PHBI Balance Sheet
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $140K-13.9% | $163K-23.0% | $212K+1.3% | $209K+9.3% | $191K-3.6% | $198K-44.5% | $358K-4.1% | $373K |
| Current Assets | $51K-30.6% | $74K | N/A | $209K | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $5K-28.0% | $7K-70.4% | $25K+211.4% | $8K-67.0% | $24K+696.8% | $3K-70.9% | $10K-58.6% | $25K |
| Inventory | $9K-3.1% | $10K | N/A | $0 | N/A | N/A | N/A | N/A |
| Accounts Receivable | $606+6.5% | $569+22.4% | $465+21.4% | $383+21.2% | $316+351.4% | $70 | N/A | $290 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.2M+6.7% | $2.1M+4.7% | $2.0M-1.1% | $2.0M-4.6% | $2.1M-18.1% | $2.6M+33.9% | $1.9M-6.0% | $2.1M |
| Current Liabilities | $2.2M+5.4% | $2.1M+7.4% | $1.9M+0.4% | $1.9M-3.9% | $2.0M-22.1% | $2.6M+34.5% | $1.9M-6.2% | $2.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.1M-8.4% | -$1.9M-10.9% | -$1.8M+1.4% | -$1.8M+6.1% | -$1.9M+21.3% | -$2.4M-51.6% | -$1.6M+6.4% | -$1.7M |
| Retained Earnings | -$13.0M-1.3% | -$12.8M-1.5% | -$12.6M-0.3% | -$12.6M-0.9% | -$12.5M+2.0% | -$12.7M-8.9% | -$11.7M+0.2% | -$11.7M |
PHBI Cash Flow Statement
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8K+121.9% | -$34K-75.7% | -$19K+78.9% | -$92K+29.0% | -$130K-133.0% | -$56K+62.4% | -$149K-170.8% | -$55K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $18K-6.1% | $19K-60.3% | $47K | $0-100.0% | $113K+75.1% | $65K-52.5% | $136K+266.3% | $37K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PHBI Financial Ratios
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.8%+37.1pp | -2.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -19520.5% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -27291.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -116.1% | N/A | -18.6% | N/A | 131.8% | N/A | 5.2% | N/A |
| Current Ratio | 0.02-0.0 | 0.04 | N/A | 0.11 | N/A | N/A | N/A | N/A |
| Debt-to-Equity | -1.07+0.0 | -1.08+0.1 | -1.150.0 | -1.14-0.0 | -1.13-0.0 | -1.08+0.1 | -1.230.0 | -1.22 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.11), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Pharmagreen Biotech Inc profitable?
No, Pharmagreen Biotech Inc (PHBI) reported a net income of -$876K in fiscal year 2022.
What is Pharmagreen Biotech Inc's operating cash flow?
Pharmagreen Biotech Inc (PHBI) generated -$427K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Pharmagreen Biotech Inc's total assets?
Pharmagreen Biotech Inc (PHBI) had $209K in total assets as of fiscal year 2022, including both current and long-term assets.
What is Pharmagreen Biotech Inc's current ratio?
Pharmagreen Biotech Inc (PHBI) had a current ratio of 0.11 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Pharmagreen Biotech Inc's debt-to-equity ratio?
Pharmagreen Biotech Inc (PHBI) had a debt-to-equity ratio of -1.14 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pharmagreen Biotech Inc's return on assets (ROA)?
Pharmagreen Biotech Inc (PHBI) had a return on assets of -419.0% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Pharmagreen Biotech Inc's cash runway?
Based on fiscal year 2022 data, Pharmagreen Biotech Inc (PHBI) had $8K in cash against an annual operating cash burn of $427K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Pharmagreen Biotech Inc's debt-to-equity ratio negative or unusual?
Pharmagreen Biotech Inc (PHBI) has negative shareholder equity of -$1.8M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Pharmagreen Biotech Inc's Piotroski F-Score?
Pharmagreen Biotech Inc (PHBI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pharmagreen Biotech Inc's earnings high quality?
Pharmagreen Biotech Inc (PHBI) has an earnings quality ratio of 0.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Pharmagreen Biotech Inc?
Pharmagreen Biotech Inc (PHBI) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.